{
    "clinical_study": {
        "@rank": "69006", 
        "arm_group": [
            {
                "arm_group_label": "YXBCM01 granule", 
                "arm_group_type": "Experimental", 
                "description": "YXBCM01 granule 1.1g os once a day for 12weeks."
            }, 
            {
                "arm_group_label": "YXBCM01 granule low dose group", 
                "arm_group_type": "Experimental", 
                "description": "YXBCM01 granule 5.5g os once a day for 12weeks."
            }, 
            {
                "arm_group_label": "placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Placebo granule 1.1g os once a day for 12weeks."
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to evaluate the efficacy and safety of Chinese herbal YXBCM01\n      granule for stable plaque psoriasis, with blood stasis syndrome of  Chinese Medicine."
        }, 
        "brief_title": "Clinical Trial of YXBCM01 Granule to Treat Stable Plaque Psoriasis", 
        "completion_date": {
            "#text": "December 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Plaque Psoriasis", 
        "condition_browse": {
            "mesh_term": "Psoriasis"
        }, 
        "detailed_description": {
            "textblock": "Psoriasis is an immune-abnormal, chronic, proliferative skin disease characterized by scaly,\n      erythematous patches and papules. An epidemiological survey found Chinese prevalence showed\n      an upward trend in recent years. The disease has great influence on patients'\n      appearance,health and quality of life. Some Chinese Herbal Medicine (CHM) therapies have\n      shown long lasting therapeutic effect on controlling psoriasis vulgaris and with minimal\n      side effects.CHM can alleviate the symptoms effectively,and reduce the recurrence rate of\n      diseases. YXBCM01 granule is one kind of CHM which is observed effective and safe to treat\n      stable stable plaque psoriasis with blood stasis syndrome in clinical practice."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Stable plaque psoriasis, duration > 1 year.\n\n          2. Patients with Chinese medicine blood stasis syndrome. (2)18 to 65 years old, male or\n             female patient.\n\n          3. Mild psoriasis:3\uff1cPASI\u226410, and BSA\u226410%.\n\n          4. Informed consent.\n\n        Exclusion Criteria:\n\n          1. Guttate psoriasis, inverse psoriasis or exclusively involves the face;\n\n          2. Acute progression of psoriasis, and erythroderma tendency.Not blood stasis\n             syndrome.Not stable psoriasis.\n\n          3. Pregnant, lactating, or which one plan to become pregnant in a year;\n\n          4. SAS\uff08Self-rating Anxiety Scale\uff09> 50 or SDS\uff08Self-rating Depression Scale\uff09> 53, or with\n             other psychiatric disorders;\n\n          5. With history of cardiovascular, respiratory, digestive, urinary, and hematologic\n             disease, which can't controlled through common treatment. Either with cancer,\n             infection, electrolyte imbalance, acid-base disturbance and calcium metabolic\n             disorder.\n\n          6. Allergic to any medicine or ingredients used in this study.\n\n          7. Participating other clinical trials or participated within 1 month.\n\n          8. Topical treatments (i.e. corticosteroids, Retinoic acid) within 2 weeks; systemic\n             therapy or phototherapy (UVB and PUVA) within 4 weeks; biological therapy within 12\n             weeks.\n\n          9. Patients need systemic treatment prescribed by doctors."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "65 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "384", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "May 24, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02153840", 
            "org_study_id": "201105"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "YXBCM01 granule", 
                    "YXBCM01 granule low dose group"
                ], 
                "intervention_name": "YXBCM01 granule", 
                "intervention_type": "Drug", 
                "other_name": "Chinese Hebal Medicine"
            }, 
            {
                "arm_group_label": "placebo", 
                "intervention_name": "placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": "Stable Plaque Psoriasis", 
        "lastchanged_date": "May 31, 2014", 
        "location": [
            {
                "contact": {
                    "email": "luchuanjian888@vip.sina.com", 
                    "last_name": "Chuanjian Lu, Doctor", 
                    "phone": "(8620)81887233", 
                    "phone_ext": "31223"
                }, 
                "contact_backup": {
                    "email": "wenzehuai@139.com", 
                    "last_name": "Zehuai Wen, Doctor", 
                    "phone": "\uff0886\uff0913903008091"
                }, 
                "facility": {
                    "address": {
                        "city": "Guangzhou", 
                        "country": "China", 
                        "state": "Guangdong"
                    }, 
                    "name": "Guangdong Provincial Hospital of Traditional Chinese Medicine"
                }, 
                "investigator": [
                    {
                        "last_name": "Chuanjian Lu, Doctor", 
                        "role": "Principal Investigator"
                    }, 
                    {
                        "last_name": "Danni Yao", 
                        "role": "Sub-Investigator"
                    }
                ], 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "chaxushan@sina.com", 
                    "last_name": "Xushan Cha, Doctor", 
                    "phone": "\uff0886\uff0913926439380"
                }, 
                "facility": {
                    "address": {
                        "city": "Guangzhou", 
                        "country": "China", 
                        "state": "Guangdong"
                    }, 
                    "name": "The First Affiliated Hospital of Guangzhou University of Traditional Chinese Medicine"
                }, 
                "investigator": {
                    "last_name": "Xushan Cha, Doctor", 
                    "role": "Sub-Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "Lmjjhr@163.com", 
                    "last_name": "Mingjiu Li", 
                    "phone": "\uff08086\uff0913392634299"
                }, 
                "facility": {
                    "address": {
                        "city": "Guangzhou", 
                        "country": "China", 
                        "state": "Guangdong"
                    }, 
                    "name": "Chronic Disease Prevention and Control Station of Panyu District in Guangzhou"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "China"
        }, 
        "number_of_arms": "3", 
        "official_title": "A Double-blind, Randomized, Placebo-controlled Trial of YXBCM01 Granule for Stable Plaque Psoriasis", 
        "overall_contact": {
            "email": "luchuanjian888@vip.sina.com", 
            "last_name": "Chuanjian Lu, Doctor", 
            "phone": "(8620)81887233", 
            "phone_ext": "31223"
        }, 
        "overall_contact_backup": {
            "email": "wenzehuai@139.com", 
            "last_name": "Zehuai Wen, Doctor", 
            "phone": "(86)13903008091"
        }, 
        "overall_official": {
            "affiliation": "Guangdong Provincial Hospital of Traditional Chinese Medicine", 
            "last_name": "Chuanjian Lu, Doctor", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "China: Ethics Committee", 
                "China: Ministry of Health"
            ], 
            "has_dmc": "Yes"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "December 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "The number of patients who achieve at least 50% improvement in PASI score from baseline.", 
            "measure": "PASI-50", 
            "safety_issue": "No", 
            "time_frame": "12 weeks (plus or minus 3 days) after treatment"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02153840"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Guangdong Provincial Hospital of Traditional Chinese Medicine", 
            "investigator_full_name": "Chuanjian Lu", 
            "investigator_title": "Doctor", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "description": "The improvement in PASI score from baseline.", 
                "measure": "PASI(Psoriasis Area and Severity Index)", 
                "safety_issue": "No", 
                "time_frame": "12 weeks (plus or minus 3 days) after treatment"
            }, 
            {
                "description": "The number of patients who achieve at least 75% improvement in PASI score from baseline.", 
                "measure": "PASI-75", 
                "safety_issue": "No", 
                "time_frame": "12 weeks (plus or minus 3 days) after treatment"
            }, 
            {
                "measure": "Pruritus Scores on the Visual Analogue Scale", 
                "safety_issue": "No", 
                "time_frame": "12 weeks (plus or minus 3 days) after treatment"
            }, 
            {
                "description": "the Body Surface Area", 
                "measure": "BSA\uff08Body Surface Area\uff09", 
                "safety_issue": "No", 
                "time_frame": "12 weeks (plus or minus 3 days) after treatment"
            }, 
            {
                "description": "the Dermatology Quality Life Index", 
                "measure": "DLQI\uff08Dermatology Life Quality Index\uff09", 
                "safety_issue": "No", 
                "time_frame": "12 weeks (plus or minus 3 days) after treatment"
            }, 
            {
                "description": "Relapse can be defined only for patients who achieve PASI50\uff0cand occurs when the improvement in the PASI score falls below 50% from the baseline PASI score.", 
                "measure": "Relapse rate in treatment period / follow-up period", 
                "safety_issue": "No", 
                "time_frame": "During the treatment period of 12 weeks / follow-up period of 12 weeks after treatment period"
            }, 
            {
                "measure": "Time interval for patients the first time to achieve PASI-50 from baseline", 
                "safety_issue": "No", 
                "time_frame": "During the treatment period of 12 weeks"
            }, 
            {
                "description": "Relapse time interval refers to the time when patients who achieve PASI-50 for the first time until first relapse occurs.", 
                "measure": "Relapse time interval", 
                "safety_issue": "No", 
                "time_frame": "During the treatment period of 12 weeks / follow-up period of 12 weeks after treatment period"
            }, 
            {
                "description": "Rebound can be defined only for patients who achieve PASI50\uff0cand occurs when the improvement in the PASI score increase up to 25% from the baseline PASI score.", 
                "measure": "Rebound rate", 
                "safety_issue": "No", 
                "time_frame": "During the treatment period of 12 weeks / follow-up period of 12 weeks after treatment period"
            }
        ], 
        "source": "Guangdong Provincial Hospital of Traditional Chinese Medicine", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Guangdong Provincial Hospital of Traditional Chinese Medicine", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "December 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}